FDA OKs First ‘Targeted Treatment’ for Rare DMD Mutation

The US Food and Drug Administration (FDA) has approved the antisense oligonucleotide casimersen (Amondys 45, Sarepta Therapeutics) injection for the treatment of patients with Duchenne muscular dystrophy (DMD) plus a rare DMD mutation, the agency has announced.  This particular mutation of the DMD gene “is amenable to exon 45 skipping,” the FDA noted in a press release. It added that […]

Read more

Cloud-enabled tumor board review enables faster insights than traditional methods

The conventional tumor board may soon be a thing of the past. Tumor boards typically comprise practitioners from multiple backgrounds, who meet to weigh a wide range of options for potential oncology treatments, study gene sequencing and assess patients’ suitability for clinical trials. They’re essential parts of the care process. But getting oncologists, pathologists, patient advocates and others together in […]

Read more

Geisinger names Dr. Jaewon Ryu its new president and CEO

Dr. Jaewon Ryu, who has served as interim president and CEO of Danville, Pennsylvania-based Geisinger for the past six months, has been approved by the health system’s board of directors to take on the role full time. He’s just the seventh chief executive in Geisinger’s century-plus existence. WHY IT MATTERS Ryu, who had served as Geiseinger’s chief medical officer since […]

Read more

Neural dust: Implantable medical devices the size of a grain of sand

Many of the diseases that afflict people today are fundamentally addressable through neuromodulation, a process by which nervous activity is regulated by way of controlling the physiological levels of several classes of neurotransmitters. Neuromodulators are a subset of neurotransmitter. Unfortunately, many challenges confront clinicians in the study of the nervous system and hinder the discovery of new treatments, said Jose […]

Read more

UPMC's data mission: balance population health and precision medicine

As both provider and payer, UPMC is not just an IDS, it’s an IDFS – what Chief Innovation Officer Dr. Rasu Shrestha describes as an “integrated delivery financial system.” Managing those twin imperatives at such as high level means lots and lots of data. “We have a lot of data across the health services group,” said Shrestha. “Clinical data, a […]

Read more